UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number: 001-43415
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
(Registrant’s Name)
3rd Floor West Side Gotanda bldg.
6-2-7 Nishi Gotanda, Shinagawa-ku,
Tokyo 1410031, Japan
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
x Form 20-F ¨ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Information Contained in this Form 6-K Report
On September 30, 2026, Instinct
Bio Technical Company Holdings Inc. (the “Company”) issued a press release (the
“Press Release”) announcing that CelSiege Biosciences has named it as a non-exclusive
authorized representative in Japan and China for IN01, a clinical-stage cancer immunotherapy, a copy of which is furnished as Exhibit 99.1
to this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”).
The information contained in this Form 6-K,
including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
EXHIBIT INDEX
| Exhibit No. |
|
Description |
| 99.1 |
|
Press Release dated September 30, 2026 |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. |
| |
|
|
| Date: October 1, 2026 |
By: |
/s/ Tomoki Nagano |
| |
|
Name: |
Tomoki Nagano |
| |
|
Title: |
Chief Executive Officer and Director |
Exhibit 99.1
BIOT Named Authorized Representative for IN01
Cancer Immunotherapy
in Japan and China
Non-exclusive appointment by CelSiege Biosciences
extends BIOT's business development activities into clinical-stage oncology
NEW YORK and TOKYO, September 30, 2026 —
INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("BIOT" or the "Company") today announced that CelSiege
Biosciences Inc. ("CelSiege") has appointed BIOT, on a non-exclusive basis, as its authorized introduction and business development
representative in Japan and the People's Republic of China for IN01, a clinical-stage cancer immunotherapy program.
Under a Letter of Authorisation signed on September 18,
2026 by Johan Indot, Founder and Director of CelSiege, BIOT may introduce the IN01 Program to prospective strategic partners, investors,
pharmaceutical and biotechnology companies, medical institutions, research organizations and investment funds in both countries. BIOT
may also facilitate preliminary discussions on potential investment, licensing, co-development, clinical development, manufacturing and
commercialization. Any definitive transaction remains subject to separate negotiations, due diligence and definitive agreements.
"We believe IN01 is a promising clinical-stage
program in the field of active cancer immunotherapy, and we are fully committed to helping build a path for this science to reach the
patients who need it," said Tomoki Nagano, Chief Executive Officer of BIOT. "Japan and China have the world's largest lung cancer
patient populations alongside world-class clinical research capabilities, placing them at the center of unmet medical needs in oncology.
We share with CelSiege a mission to bring this technology to patients. As CelSiege's authorized representative in these two markets, BIOT
will work with a strong sense of ownership to identify partners and pursue collaborations that can advance the development and commercialization
of IN01. Our enduring aspiration is to bring more smiles to patients and their families."
About IN01
According to information provided by CelSiege, IN01
is an active immunotherapy, or therapeutic cancer vaccine, targeting epidermal growth factor ("EGF"). It is designed to stimulate
the patient's immune system to produce antibodies against circulating EGF, a growth factor involved in the proliferation of certain cancer
cells. Development materials identify squamous non-small cell lung cancer ("sqNSCLC") as the lead indication, with potential
expansion into colorectal, head-and-neck and other cancers. IN01 is a clinical-stage asset and has not received marketing approval.
The Medical Need
According to the International Agency for Research
on Cancer, lung cancer was the world's most frequently diagnosed cancer in 2022, with approximately 2.5 million new cases, and the leading
cause of cancer death, with approximately 1.8 million deaths. Non-small cell lung cancer accounts for approximately 80% to 85% of lung
cancer cases, according to the American Cancer Society. Fortune Business Insights estimates the global NSCLC therapeutics market at approximately
$38.49 billion in 2025. This third-party estimate relates to a broad therapeutic category and should not be read as an estimate of the
addressable market, commercial potential or probability of success of IN01.
About CelSiege Biosciences
CelSiege Biosciences is a biotechnology company
headquartered in Marseille, France, with operations in the United States, focused on the research and development of active immunotherapies.
Its proprietary B-cell-mediated platform is designed to stimulate polyclonal antibody responses against disease-associated ligands, with
applications in oncology and other therapeutic areas.
For
more information, visit CelSiege’s corporate website.
CelSiege Biosciences
About INSTINCT BIO TECHNICAL COMPANY HOLDINGS
INC.
INSTINCT
BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) is a diversified healthcare and biotechnology company focused on developing and expanding
businesses across beauty, wellness, regenerative medicine and related healthcare sectors. Through its operations and strategic partnerships,
BIOT seeks to build an integrated platform connecting innovative healthcare technologies, products and services with growth opportunities
across Asia and other international markets. For more information, please visit https://instinct-biot.com/
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of applicable U.S. securities laws, including statements regarding BIOT's plans to identify and engage potential strategic
partners for the IN01 Program in Japan and China; potential investment, licensing, co-development, clinical development, manufacturing,
commercialization or other collaborations involving IN01; and the potential future development and regulatory approval of IN01. These
statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results
to differ materially. There can be no assurance that BIOT will identify suitable counterparties, that discussions will result in definitive
agreements or transactions, or that IN01 will successfully complete clinical development, demonstrate safety or efficacy, or receive regulatory
or marketing approval in Japan, China or any other jurisdiction. Third-party data cited in this press release has not been independently
verified by BIOT. Readers are cautioned not to place undue reliance on forward-looking statements. BIOT undertakes no obligation to update
or revise any forward-looking statements except as required by applicable law.
Contact
INSTINCT
BIO TECHNICAL COMPANY HOLDINGS INC.
Investor Relations
Email: ir@instinct-bro.com
Website: https://instinct-biot.com/
